Literature DB >> 11416722

Non-adherence to highly active antiretroviral therapy predicts progression to AIDS.

D R Bangsberg1, S Perry, E D Charlebois, R A Clark, M Roberston, A R Zolopa, A Moss.   

Abstract

Entities:  

Mesh：

Year:  2001        PMID： 11416722     DOI： 10.1097/00002030-200106150-00015

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  389 in total

Review 1.  Human immunodeficiency virus-associated dementia: an evolving disease.

Authors:  Justin C McArthur; Norman Haughey; Suzanne Gartner; Kathy Conant; Carlos Pardo; Avi Nath; Ned Sacktor
Journal:  J Neurovirol       Date:  2003-04       Impact factor: 2.643

Review 2.  Interventions to improve adherence to antiretroviral therapy in children with HIV infection.

Authors:  Deborah Bain-Brickley; Lisa M Butler; Gail E Kennedy; George W Rutherford
Journal:  Cochrane Database Syst Rev       Date:  2011-12-07

3.  Suboptimal adherence associated with virological failure and resistance mutations to first-line highly active antiretroviral therapy (HAART) in Bangalore, India.

Authors:  Maria L Ekstrand; Anita Shet; Sara Chandy; Girija Singh; Ranjani Shamsundar; Vidya Madhavan; Shanmugam Saravanan; Elsa Heylen; Nagalingeswaran Kumarasamy
Journal:  Int Health       Date:  2011-03       Impact factor: 2.473

4.  Reliability and validity of the SF-36 in HIV-infected homeless and marginally housed individuals.

Authors:  E D Riley; D R Bangsberg; S Perry; R A Clark; A R Moss; A W Wu
Journal:  Qual Life Res       Date:  2003-12       Impact factor: 4.147

5.  A commitment contract to achieve virologic suppression in poorly adherent patients with HIV/AIDS.

Authors:  Marcella Alsan; John Beshears; Wendy S Armstrong; James J Choi; Brigitte C Madrian; Minh Ly T Nguyen; Carlos Del Rio; David Laibson; Vincent C Marconi
Journal:  AIDS       Date:  2017-07-31       Impact factor: 4.177

6.  Increase in single-tablet regimen use and associated improvements in adherence-related outcomes in HIV-infected women.

Authors:  David B Hanna; Nancy A Hessol; Elizabeth T Golub; Jennifer M Cocohoba; Mardge H Cohen; Alexandra M Levine; Tracey E Wilson; Mary Young; Kathryn Anastos; Robert C Kaplan
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-15       Impact factor: 3.731

7.  Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.

Authors:  R M Savic; A Barrail-Tran; X Duval; G Nembot; X Panhard; D Descamps; C Verstuyft; B Vrijens; A-M Taburet; C Goujard; F Mentré
Journal:  Clin Pharmacol Ther       Date:  2012-10-03       Impact factor: 6.875

8.  Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial.

Authors:  Frederick L Altice; Duncan Smith-Rohrberg Maru; R Douglas Bruce; Sandra A Springer; Gerald H Friedland
Journal:  Clin Infect Dis       Date:  2007-08-13       Impact factor: 9.079

9.  Adherence to antiretroviral therapy in a context of universal access, in Rio de Janeiro, Brazil.

Authors:  R H Remien; F I Bastos; V Terto Jnr; J C Raxach; R M Pinto; R G Parker; A Berkman; M A Hacker
Journal:  AIDS Care       Date:  2007-07

10.  The association between poor antiretroviral adherence and unsafe sex: differences by gender and sexual orientation and implications for scale-up of treatment as prevention.

Authors:  Robert H Remien; Curtis Dolezal; Glenn J Wagner; Kathy Goggin; Ira B Wilson; Robert Gross; Marc I Rosen; Jie Shen; Jane M Simoni; Carol E Golin; Julia H Arnsten; David R Bangsberg; Honghu Liu
Journal:  AIDS Behav       Date:  2014-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.